title: When choosing statin therapy: the case for generics.
abstract: The development of "Top 5" lists across specialties and at regular intervals can help to remind physicians that optimal care is often possible at a lower cost. For purposes of cardiovascular risk reduction, generic statins, or their brand equivalents if priced similarly, remain the appropriate choice for dyslipidemic patients initiating statin therapy. In this article, we review the evidence supporting the choice of generic statins.
authors.affiliation: Cedars-Sinai Medicine, Department of Medicine, Cedars-Sinai Health System, Los Angeles, CA 90049, USA. Jonas.Green@cshs.org
authors.forename: Jonas B
authors.initials: JB
authors.lastname: Green
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Ross
authors.forename: Cynthia A
authors.initials: CA
authors.lastname: Jackevicius
authors.forename: Nilay D
authors.initials: ND
authors.lastname: Shah
authors.forename: Harlan M
authors.initials: HM
authors.lastname: Krumholz
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002755:Choice Behavior; D016568:Drugs, Generic; D050171:Dyslipidemias / Q000150:complications; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013810:Therapeutic Equivalency
chemical_list: D016568:Drugs, Generic; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors